Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Jabran Kundi

NVO vs. LLY: Novo’s CEO Says Confidence Is Gone. Lilly Is Winning 7 in 10 New Seniors.

Sept. 21 showed exactly where the weight-loss drug race stands. Eli Lilly (LLY) CEO Dave Ricks told CNBC that about 700,000 seniors have started weight-loss drugs since Medicare began covering them in July, and roughly 70% chose Lilly. On the same day, Novo Nordisk (NVO) held its investor day in London. CEO Mike Doustdar confirmed that Wegovy and Ozempic will lose their exclusive rights in the early 2030s, opening the door to cheaper copies. Novo’s U.S. shares fell nearly 8% in a single trading session.

Lilly Keeps Pulling Ahead

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.